|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.41 USD | +2.36% |
|
+0.50% | -7.34% |
| 12/12 | Morgan Stanley Adjusts Bristol-Myers Squibb PT to $37 From $36, Maintains Underweight Rating | MT |
| 12/12 | Arcus scraps late-stage cancer trial after weak survival data | RE |
| Capitalization | 11TCr 9.09TCr 8.49TCr 7.98TCr 15TCr 9,66000Cr 16TCr 99TCr 38TCr 4,55500Cr 40TCr 39TCr 16,62200Cr | P/E ratio 2025 * |
12.3x | P/E ratio 2026 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise value | 14TCr 12TCr 11TCr 10TCr 19TCr 12,64400Cr 21TCr 1,29300Cr 50TCr 5,96100Cr 52TCr 51TCr 21,75500Cr | EV / Sales 2025 * |
2.91x | EV / Sales 2026 * | 3.02x |
| Free-Float |
67.93% | Yield 2025 * |
4.72% | Yield 2026 * | 4.83% |
Last Transcript: Bristol-Myers Squibb Company
| 1 day | +2.36% | ||
| 1 week | +0.50% | ||
| Current month | +6.52% | ||
| 1 month | +7.77% | ||
| 3 months | +13.44% | ||
| 6 months | +5.35% | ||
| Current year | -7.34% |
| 1 week | 50.33 |  | 52.99 |
| 1 month | 45.26 | | 52.99 |
| Current year | 42.52 | | 63.33 |
| 1 year | 42.52 | | 63.33 |
| 3 years | 39.35 | | 77.21 |
| 5 years | 39.35 | | 81.44 |
| 10 years | 39.35 | | 81.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 01/11/2023 | |
David Elkins
DFI | Director of Finance/CFO | 57 | 20/11/2019 |
| Compliance Officer | - | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 01/04/2024 | |
Peter Arduini
BRD | Director/Board Member | 60 | 01/04/2016 |
Theodore Samuels
BRD | Director/Board Member | 70 | 21/02/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 12.97% | 303 M€ | -21.05% | - |
| 4.01% | 26 M€ | +12.27% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.36% | +0.50% | -6.04% | -32.24% | 11TCr | |
| +1.80% | +1.70% | +30.21% | +186.49% | 92TCr | |
| +0.75% | +4.78% | +44.31% | +18.06% | 51TCr | |
| -0.29% | -1.22% | +28.81% | +35.52% | 39TCr | |
| -0.35% | +1.90% | +25.12% | +3.11% | 34TCr | |
| -1.12% | -1.09% | +28.43% | +18.70% | 28TCr | |
| -0.45% | -1.48% | +20.24% | +24.41% | 25TCr | |
| +1.30% | +0.58% | -1.67% | -9.57% | 25TCr | |
| +0.45% | +3.73% | -57.41% | -30.85% | 22TCr | |
| +0.11% | -3.68% | +17.41% | +16.70% | 17TCr | |
| Average | +0.46% | +0.57% | +12.94% | +23.03% | 34.49TCr | |
| Weighted average by Cap. | +0.60% | +1.13% | +21.00% | +57.24% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.8TCr 4.09TCr 3.82TCr 3.59TCr 6.61TCr 4,34500Cr 7.22TCr 44TCr 17TCr 2,04900Cr 18TCr 18TCr 7,47700Cr | 4.41TCr 3.76TCr 3.51TCr 3.3TCr 6.07TCr 3,99500Cr 6.64TCr 41TCr 16TCr 1,88300Cr 17TCr 16TCr 6,87300Cr |
| Net income | 832.01Cr 708.75Cr 661.96Cr 622.34Cr 1.15TCr 75TCr 1.25TCr 7.7TCr 2.99TCr 36TCr 3.12TCr 3.06TCr 1,29600Cr | 924.68Cr 787.7Cr 735.69Cr 691.66Cr 1.27TCr 84TCr 1.39TCr 8.56TCr 3.33TCr 39TCr 3.47TCr 3.4TCr 1,44100Cr |
| Net Debt | 3.29TCr 2.81TCr 2.62TCr 2.46TCr 4.54TCr 2,98300Cr 4.96TCr 30TCr 12TCr 1,40600Cr 12TCr 12TCr 5,13300Cr | 2.64TCr 2.25TCr 2.1TCr 1.97TCr 3.63TCr 2,38900Cr 3.97TCr 24TCr 9.49TCr 1,12600Cr 9.9TCr 9.69TCr 4,11100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/25/12 | 52.41 $ | +2.36% | 1,90,46,726 |
| 11/25/11 | 51.20 $ | -0.02% | 96,84,307 |
| 10/25/10 | 51.21 $ | +1.11% | 1,21,32,410 |
| 09/25/09 | 50.65 $ | -1.97% | 1,27,15,403 |
| 08/25/08 | 51.67 $ | -0.92% | 1,52,78,685 |
Delayed Quote Nyse, December 13, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition